Introduction
============

Psychotropic medications, such as phenothiazine, thioxanthene, or butyrophenone-type neuroleptics, lithium salts, tricyclic antidepressants, irreversible monoamine oxidase inhibitors, and benzodiazepines, have been used for more than 60 years in clinical practices. Most of the new generation of psychotropics have appeared after 1985 and, even more recently, atypical antipsychotics, antiepileptics as mood stabilizers, and antidementia medications. Compared with the old medications, the newer medications have similar efficacies but better tolerability and fewer side effects.[@b1-ndt-12-897],[@b2-ndt-12-897]

Many international studies have directly or indirectly noted how clinical practice and actual psychotropic prescribing practices in both hospital and outpatient settings do not always agree with internationally recognized guidelines.[@b1-ndt-12-897]--[@b4-ndt-12-897] A proper evaluation of the difference between actual practice and a theoretical, gold standard-oriented approach may help to avoid several erroneous trends that may negatively affect patient outcomes and other pharmacoeconomic issues. For example, some international studies have reported an increase in the practice of polypharmacy, that is, the use of four or more medications specially by the elderly population,[@b5-ndt-12-897] and the prescription of new and expensive medications and low-dose and off-label drugs to women and children.[@b4-ndt-12-897] Most of the studies that evaluated use of psychotropic drugs have reported a high rate of prescriptions for multiple drugs, which usually occurs when there was no improvement in clinical symptoms.[@b2-ndt-12-897] A UK survey found that more than 50% of hospitalized patients were receiving more than one type of antipsychotic medication.[@b6-ndt-12-897]

Although hospitalization is often preferred in many major psychiatric diseases, such as schizophrenia or bipolar disorder, treatment as outpatients is also employed to maintain community ties and a patient's autonomy,[@b7-ndt-12-897] thereby resulting in satisfactory treatment results while still reducing overall costs.[@b8-ndt-12-897] Outpatient psychiatric services often complement inpatient ones and limit the excessive use of mental health services; nonetheless, patient populations for whom substitution is possible should be accurately analyzed to avoid an overall reduction of care for patients who fail to follow-up with their treatment.[@b9-ndt-12-897],[@b10-ndt-12-897]

The overall situation of mental health services and prescribing practices in Saudi Arabia has been previously investigated in other studies, but more data are still needed to successfully assess the trends and prescribing habits and to gain a broader view.[@b11-ndt-12-897] Studies with a larger scope have focused more on the mental health system's general situation rather than on a detailed view of the current trends for inpatient and outpatient psychotropic medication prescriptions,[@b12-ndt-12-897] whereas other studies smaller in scope have only analyzed local data.[@b13-ndt-12-897] The objective of the current study was to study the pattern of psychotropic medication use and compare the frequency of prescribing psychotropic medications between inpatient and outpatient settings in Saudi Arabia.

Methods
=======

Setting
-------

The current study was conducted among patients seeking psychiatric advice at major hospitals in Saudi Arabia. The patients were recruited from a number of hospitals located in the Central, Eastern, Western, Northern, and Southern regions of Saudi Arabia. The hospitals included in the study were King Khalid University Hospital in Riyadh and Zulfi General Hospital (Central region), Jeddah Mental Health Hospital (Western region), Al Amal Complex for Mental Health -- Dammam (Eastern region), Aljouf Mental Health Hospital (Northern region), and Abha Mental Health Hospital (Southern region). King Khalid University Hospital is a university-affiliated governmental hospital, whereas the other hospitals are government-funded hospitals under the authority of the Ministry of Health. All of the hospitals included in this study provide free psychiatric inpatient and outpatient health care services.

Study design
------------

A cross-sectional observational study was conducted between July 2012 and June 2014. The study obtained all of the required ethical approvals from the Institutional Review Board at the Faculty of Medicine at King Saud University in Riyadh and administrative approvals from the respective hospitals. The study was funded by the National Plan for Science and Technology Strategic Grants Program.

Population
----------

Male and female patients seeking psychiatric help from the included hospitals during the study period were asked to join the study. Those who signed the informed consent form and were currently or had been previously using psychotropic medications, irrespective of the patient's type of psychiatric diagnosis and the duration of the disease, were included.

Data collection
---------------

A mini-interview form was developed, which included sociodemographic characteristics, detailed current and previous psychotropic medication use (including the name of the medication, dose, and duration), and current psychiatric diagnoses. The information was mainly obtained by reviewing each patient's chart. Unclear/missing information was confirmed by interviewing the patient and/or his/her family. Trained psychiatric residents/staff were responsible for chart review and conducting interviews with the patients and/or their families.

Classification of psychotropic medications
------------------------------------------

Both the individual psychotropic medications and their pharmacologic groups were used in the analysis. These medications and groups include antidepressants (selective serotonin reuptake inhibitors, tricyclics, and others), antipsychotics (low potency first-generation and high potency first- and second-generation), antianxiety medications, and mood stabilizers.

Classification of psychiatric diagnosis
---------------------------------------

For the purpose of data analysis, the psychiatric diagnosis of the studied patients was classified under seven categories. "Primary psychotic disorders" included schizophrenia, schizoaffective disorder, delusional disorder, and brief psychotic disorder. "Primary bipolar disorders" included bipolar disorder and its features. "Primary depressive disorders" included major depressive disorder and dysthymic disorder. "Primary anxiety disorders" included generalized anxiety disorder, obsessive compulsive disorder, social anxiety disorder, specific phobias, panic disorder, post-traumatic stress disorder, and acute stress disorder. "Personality disorders" included mixed personality disorder, paranoid personality disorder, antisocial personality disorder, and borderline personality disorder. "Secondary psychiatric disorders" included psychotic disorder due to another medical condition, depression due to another medical condition, dementia, substance use disorder, and substance-induced depressive disorder. "Other disorders" included somatic symptom disorder, mental retardation, conversion disorder, attention deficit hyperactivity disorder, dissociative disorder, primary insomnia, adjustment disorder, enuresis disorder, trichotillomania, and anorexia nervosa.

Statistical analysis
--------------------

The data are presented in frequencies and percentages for categorical data and mean values and standard deviations for continuous data. Individual psychiatric diagnosis and psychotropic medications were categorized into standard groups. Significant differences between inpatient and outpatient settings as they pertained to sociodemographics, psychotropic medication use, and psychiatric diagnosis were tested using the chi-square test or Fisher's exact test (as appropriate) for categorical data and the Student's *t*-test for continuous data. All *P*-values were two-tailed, and a *P*-value \<0.05 was considered a significant value. SPSS software (release 20.0, SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.

Results
=======

A total of 1,246 patients (464 inpatients and 782 outpatients) were included in the current analysis.

Demographic characteristics
---------------------------

[Table 1](#t1-ndt-12-897){ref-type="table"} demonstrates the demographic characteristics of inpatients and outpatients studied. In terms of age, both types of patients were categorized into three categories, that is, \<40, 40--60, and \>60 years. Inpatients and outpatients were found to show similar trend with the average majority (58.9%) lying below the age of 40 followed by the age of 40--60 (35.9%) and \>60 (5.2%). Similarly, no major sex difference was noticed with an average of 52.3% males and 47.7% females. Approximately 45.6% of the patients were married, and 54.4% were unmarried: single (44.1%), divorced (9.2%), or widowed (1.1%). However, significant difference (*P*\<0.001) was obtained in this case where inpatients have a majority of single and divorced persons while outpatients have a maximum number of married and widowed persons.

Further, \~75.9% of the patients had children, in which the percentage of inpatients was more who possess one to three children in comparison with outpatients while the opposite was obtained where the number of children exceeds three.

All inpatients and outpatients were also recorded for their education level as illiterates, possess secondary education or less, and university level. No noticeable differences were observed in any of the education levels when compared between inpatients and outpatients, with an average majority (65.0%) falling in the category of less than secondary education.

When analyzed for their job status, partial variations were observed in patients who were in government job and unemployed persons. While more number of outpatients was recorded in the former condition, more number of inpatients was found in the latter status. However, overall among all the job status (private, government, business, or unemployed), the highest average (71.4%) belongs to unemployed patients. Approximately 61.9% of the total patients had a moderately low family monthly income (6,000 Saudi Riyal \[SR\] or less). Marked differences (*P*\<0.001) were found with the number of inpatients comparatively more in low income category (\<3,000 SR) and number of outpatients in high income category (\>9,000 SR). The majority (80.9%) of the total patients reside in urban communities, with no major differences between the inpatient and outpatient count. The average body mass index was 28.6±7.6, and 67.1% of patients were either overweight or obese. Approximately 45.7% of patients were either current (33.7%) or previous (12.0%) smokers.

Overall, compared with outpatients, inpatients were more likely to be male (*P*=0.004), unmarried (*P*\>0.001), have less number of children (1--3; *P*=0.002), unemployed (*P*=0.001), have a lower family income (\>3,000 SR; *P*\<0.001), live in rural communities (*P*\<0.001), have a lower body mass index (*P*=0.001), and smokers (*P*\<0.001); however, there were no differences with regard to age or educational levels.

Current and previous use of antipsychotic medications in inpatients and outpatients
-----------------------------------------------------------------------------------

[Figure 1](#f1-ndt-12-897){ref-type="fig"} illustrates the overall usage of psychotropic medications in current as well as in previous scenario and the following frequencies were recorded: antipsychotics (76.6% and 76.1%, respectively), antidepressants (41.4% and 38.5%, respectively), mood stabilizers (27.9% and 23.5%, respectively), and antianxiety medications (6.2% and 3.6%, respectively). Compared to outpatients, the current use of medications for inpatients was more frequent (93.8% vs 89.9%, *P*=0.019), whereas their previous medication use was approximately similar (76.3% vs 78.1%, *P*=0.452). Additionally, inpatients were more likely to currently (2.1±0.8 vs 1.8±0.7, *P*\<0.001) and previously (2.0±0.8 vs 1.7±0.7, *P*\<0.001) use multiple medications compared with outpatients.

The current and previous uses of different psychotropic medications in inpatients and outpatients are shown in [Tables 2](#t2-ndt-12-897){ref-type="table"}[](#t3-ndt-12-897){ref-type="table"}--[4](#t4-ndt-12-897){ref-type="table"}. With very few exceptions, different groups of antipsychotic medications were both currently and previously more frequently used among inpatients compared with outpatients ([Table 2](#t2-ndt-12-897){ref-type="table"}). For example, antipsychotic medications were currently used for 94.3% of inpatients and 65.7% for outpatients (*P*\<0.001). This trend was similarly observed in the heavily used second-generation group and less commonly used high potency first-generation groups (*P*\<0.001 for all), but not in low potency first-generation group. However, the different groups of antidepressant medications were both currently and previously more frequently used among outpatients compared with inpatients ([Table 3](#t3-ndt-12-897){ref-type="table"}). For example, any antidepressant medications were currently used in 54.1% of outpatient settings and 20.9% of inpatient settings (*P*\<0.001). This trend was similarly observed within the commonly used groups, such as selective serotonin reuptake inhibitors, and with the less commonly used tricyclics and other types of anti-depressants (*P*\<0.001 for all). Current and previous uses of mood stabilizers and antianxiety medications were more frequently observed among inpatients compared with outpatients ([Table 4](#t4-ndt-12-897){ref-type="table"}). For example, mood stabilizers were currently used for 40.7% of inpatients and 20.1% of outpatients (*P*\<0.001), and antianxiety medications were currently used for 13.3% of inpatients and 1.8% of outpatients (*P*\<0.001).

[Table 5](#t5-ndt-12-897){ref-type="table"} shows the current prevalence in the prescription of psychotropic medications according to psychiatric diagnosis in both inpatient and outpatient settings. Antipsychotic medications were heavily used (more than 85%) in almost all inpatient psychiatric diagnosis, with the exception of primary anxiety and depressive disorders. Additionally, antipsychotic use was more frequent among inpatients than outpatients for all psychiatric diagnosis, with the exception of personality and secondary psychiatric disorders. Antidepressant medications were heavily used (80% or more) in outpatient settings for primary anxiety disorders, primary depressive disorders, and personality disorders. Additionally, antidepressant use was more common for outpatients than for inpatients, especially for those with primary anxiety disorders and primary bipolar disorders. Mood stabilizers were frequently used for primary bipolar disorders among inpatients and outpatients (\~75%), and their use was generally higher among inpatients than among outpatients. Antianxiety medications were largely administered (14%--27%) for primary bipolar disorders, primary anxiety disorders, and personality disorders, mainly among inpatients.

Among all of the participants, lithium was only used by 2.6% of participants, compared to 26.7% of participants using various anticonvulsants (sodium valproate 18.6%, carbamazepine 5.8%, and lamotrigine 2.3%). Specifically, among women of childbearing age (18--45 years), sodium valproate was the most used mood-stabilizing agent (20.8%), whereas lithium was used only by 3.6%. Moreover, during pregnancy, there is a trend of preferring sodium valproate as a mood-stabilizing agent (7.7%) over lithium (0%), although the small sample size of the pregnant participants (15 participants, 2.5%) makes it difficult to attain statistically significant results.

Among elderly patients (older than 60 years), 75.9% received antipsychotics, mainly second-generation drugs (67.2%), whereas only 41% received antidepressants and 13.8% received mood stabilizers.

Discussion
==========

The present study represented and analyzed data about the use of psychotropic medications in inpatients and outpatients from six hospitals in Saudi Arabia. These data clearly indicate that a large percentage of the total inpatient and outpatient participants (77%, [Figure 1](#f1-ndt-12-897){ref-type="fig"}) received at least one antipsychotic drug while other drugs were prescribed in much smaller percentages, including antidepressants (41%), mood stabilizers (28%), and antianxiety drugs (6%). Further, it was also noticed that in comparison to outpatients (65.7%), almost all hospitalized patients (94.3%) were more often treated with at least one antipsychotic medication. On the contrary, a much larger percentage of outpatients were treated with antidepressants of any kind compared with inpatients (54.1% vs 20.9%, [Table 3](#t3-ndt-12-897){ref-type="table"}). The use of antipsychotic medications for the treatment of several major psychiatric diseases, including depression,[@b5-ndt-12-897] is becoming common practice. The present data suggest that inpatients suffering from depression are more often managed by using psychotropic medications, which may necessitate a high level of care for their appropriate prescription and dosing.[@b3-ndt-12-897] It is to be noticed that treatment with antipsychotic medications (alone or in combination) showed a better response rate only if the patient suffers from major psychotic depression,[@b6-ndt-12-897] and these drugs may possess severe adverse side effects that could cause negative outcomes[@b7-ndt-12-897],[@b8-ndt-12-897] and could increase morbidity and mortality from a range of medical causes.[@b9-ndt-12-897] Considering the overuse of psychotropic medications as also indicated by the present study data, it is strongly recommended that great care and attention should be paid while prescribing these medications specifically for the agents which lack adequate scientific evidence.[@b4-ndt-12-897] A similar trend was also found in case of mood stabilizers and antianxiety drugs where frequency of prescription of these drugs was more in inpatients (40.7% and 13.3%) than outpatients (20.1% and 1.8%, [Table 4](#t4-ndt-12-897){ref-type="table"}).

The present study also noticed that patients on antipsychotic medications in Saudi Arabia possess several risk factors, such as smoking, dyslipidemia, overweight, and obesity. As shown in the demographic characteristics in [Table 1](#t1-ndt-12-897){ref-type="table"}, \~45.7% of the patients were either current (33.7%) or previous (12.0%) smokers, and 67.1% of them were either overweight or obese. While these risk factors are reportedly associated with major mental illnesses, such as schizophrenia or bipolar disorder,[@b13-ndt-12-897],[@b14-ndt-12-897] they also lead to increased susceptibility for progression of diabetes, weight gain, and other metabolic and cardiovascular diseases.[@b11-ndt-12-897],[@b12-ndt-12-897] Further, association of other demographic factors was also studied for all the participants. The study findings revealed that more than half of the patients (54.4%, [Table 1](#t1-ndt-12-897){ref-type="table"}) are unmarried -- single (44.1%), divorced, (9.2%), or widowed (1.1%), although approximately three-quarters of them (75.9%) had at least one child. It is known that family support and social interactions play a crucial role in reducing psychotic episodes, and encourage patients to improve their compliance with drug treatments.[@b15-ndt-12-897],[@b16-ndt-12-897] Since a large percentage of Saudi Arabian psychiatric patients live in unstable family environments or alone, a series of health policies focusing on a more attentive follow-up treatment after discharge should be considered as a critical part of treatment. Further, a majority of these psychiatric patients were unemployed (71.4%), perhaps either due to being illiterate (21.5%) or with lowest education (65.0%), thereby living in poverty (29.7% of them had a monthly family income of \<3,000 SR) ([Table 1](#t1-ndt-12-897){ref-type="table"}). It is still not clear whether these factors either contribute to the increased prevalence or outcome of psychiatric disorders; previous findings also reported a similar correlation between poverty and/or social vulnerability with mental illness in other countries.[@b17-ndt-12-897],[@b18-ndt-12-897]

Second-generation antipsychotics are vastly preferred to both high- and low potency first-generation antipsychotics (68% total patients vs 6% and 17%, [Figure 1](#f1-ndt-12-897){ref-type="fig"} and [Table 2](#t2-ndt-12-897){ref-type="table"}) due to their better safety profiles and improved tolerability.[@b19-ndt-12-897] However, a strong underuse of clozapine can be noted (only 3.1% of total inpatients and 2.4% of total outpatients, as shown in [Table 2](#t2-ndt-12-897){ref-type="table"}), even though this drug is highly recommended among the other antipsychotics.[@b1-ndt-12-897] Clozapine underuse has also been reported in the USA and the UK, which may be caused by a tendency on the clinician's part to overestimate the relevance and severity of side effects.[@b20-ndt-12-897]--[@b22-ndt-12-897] Further, aggressive marketing of other second-generation antipsychotics from pharmaceutical companies may also be a reason why clozapine use is decreasing in hospitals all over the world, including in Saudi Arabia.[@b23-ndt-12-897] Several studies suggested that detailed marketing campaigns from pharmaceutical companies involved presentation of inaccurate or suppressed data and even more the criteria for mental disorders were in fact stretched to target a vast range of patients.[@b24-ndt-12-897],[@b25-ndt-12-897] Several pharmaceutical companies adopted aggressive sales strategies, such as, advertising directly to consumers, influencing prescribers, and paying physicians to market to their peers, presenting overly optimistic cost-effectiveness research, providing free drug samples, sponsoring medical education and patient advocacy groups, and publication of biased results, in order to push widespread usage of second-generation antipsychotics.[@b26-ndt-12-897]

Our data also confirm that mood stabilizers (especially sodium valproate) are often used in addition to primary therapy with antipsychotics for the treatment of most cases of bipolar disorder (77.2%, [Table 5](#t5-ndt-12-897){ref-type="table"}). Although this trend is positive, as prescribing sodium valproate in combination with antipsychotics provided better outcomes with mania than with antipsychotic medications alone, effectively lowering the antipsychotic medications' dosages and consequently their side effects,[@b27-ndt-12-897] it should also be noted that valproate and carbamazepine are much more frequently used to treat bipolar disorder compared to lithium salt, which should be the current gold standard (343 and 130 total patients for valproate and carbamazepine, respectively, compared to just 55 total patients for lithium).[@b28-ndt-12-897] Other international studies have shown similar trends, suggesting that although lithium remains the gold standard of treatment, newer agents may sometimes be considered advances in treatment in local clinical practice and habits.[@b28-ndt-12-897],[@b29-ndt-12-897] Moreover, among women of childbearing age and even probably among pregnant women, sodium valproate was overused compared to lithium. Similar practices have also been noted in the UK[@b30-ndt-12-897] and the USA.[@b31-ndt-12-897] This practice is contrary to recent guidelines that recommend lithium use in this group, granting it higher efficacy data and a safer reproductive profile compared to sodium valproate.[@b32-ndt-12-897],[@b33-ndt-12-897] The use of sodium valproate during the first trimester has been associated with major malformations and long-term complications in the form of developmental delay, lower intelligence quotient, and a higher risk of the development of autism spectrum disorder.[@b32-ndt-12-897],[@b34-ndt-12-897],[@b35-ndt-12-897] It is worrisome that the majority of studied psychiatric patients in Saudi Arabia are receiving antipsychotic agents. Moreover, lithium is rarely used in women of childbearing age compared to valproate, which is linked to serious teratogenicity and other adverse effects.

In our study, 75.9% of elderly patients (older than 60 years) received antipsychotics, mainly second-generation drugs (67.2%), whereas only 41% received antidepressants and 13.8% received mood stabilizers. This overuse of antipsychotics among the elderly, despite warnings against this practice, can be explained by their off-label uses for behavioral disturbances that are associated with some mental disorders, such as dementia. Many factors play a role in increasing the risks associated with antipsychotic use among the elderly, including age, associated medical problems, and drug interactions. Thus, the use of antipsychotics for this population should follow recommendations and guidelines.[@b36-ndt-12-897]

It is very interesting to note how in Saudi Arabia only a very small number of patients were prescribed antianxiety drugs. In contrast, alprazolam alone was the most prescribed psychiatric medication in the USA from 2005 to 2013, with 48,465,000 total prescriptions in 2013.[@b37-ndt-12-897] The greater legal restriction on psychotropic medication use within Saudi Arabian hospitals may be one of the reasons behind this trend, although it could also be that benzodiazepines may be overused in the private sector or as street drugs.[@b38-ndt-12-897],[@b39-ndt-12-897] Overall, the study findings indicate that the prescribing practices among psychiatric patients in Saudi Arabia do not conform well to international guidelines.[@b40-ndt-12-897]--[@b42-ndt-12-897]

Conclusion
==========

Our study provides enough data to support and complement correct patient management and prescribing decisions for the use of psychotropic medications in both inpatient and outpatient settings. By investigating both previous and current treatments, we were able to produce an interesting, in-depth analysis that provides new point of view over a large and heterogeneous patient population from the five main regions of Saudi Arabia. Nevertheless, because of the use of convenience sampling, our results should be cautiously generalized to all psychiatric patients in Saudi Arabia. Another main limit is that the available data focus only on a small, 2-year time span (2012--2014); therefore, a more in-depth analysis of previous data may help to assess how prescriptions of psychotropic drugs have changed over the course of the last few years. This study may also help with assessing the burden of psychiatric illness in specific patient demographics and might be effectively used to strategically plan health resource allocation, generate new treatment hypotheses, or serve as a source of evidence that could further integrate other observational studies.
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###### 

Demographic characteristics by type of patient setting (N=1,246)

  Characteristic                                   Inpatient (N=464)   Outpatient (N=782)   Total (N=1,246)   *P*-value
  ------------------------------------------------ ------------------- -------------------- ----------------- -------------
  Age, years                                                                                                  
   Mean ± SD                                       37.6±12.1           38.6±13.6            38.2±13.0         0.191
   \<40                                            282 (61.0%)         448 (57.7%)          730 (58.9%)       0.305
   40--60                                          161 (34.8%)         284 (36.6%)          445 (35.9%)       
   \>60                                            19 (4.1%)           45 (5.8%)            64 (5.2%)         
  Sex                                                                                                         
   Male                                            267 (57.5%)         384 (49.2%)          651 (52.3%)       **0.004**
   Female                                          197 (42.5%)         397 (50.8%)          594 (47.7%)       
  Marital status                                                                                              
   Married                                         119 (27.9%)         418 (55.7%)          537 (45.6%)       \<**0.001**
   Single                                          245 (57.4%)         275 (36.6%)          520 (44.1%)       
   Divorced                                        61 (14.3%)          47 (6.3%)            108 (9.2%)        
   Widowed                                         2 (0.5%)            11 (1.5%)            13 (1.1%)         
  Number of children                                                                                          
   Mean ± SD                                       3.1 ±2.9            3.6±3.2              3.5±3.1           0.077
   None                                            39 (21.7%)          119 (25.1%)          158 (24.1%)       **0.002**
   1--3 children                                   79 (43.9%)          140 (29.5%)          219 (33.4%)       
   \>3 children                                    62 (34.4%)          216 (45.5%)          278 (42.4%)       
  Educational level                                                                                           
   Illiterate                                      96 (21.8%)          165 (21.4%)          261 (21.5%)       0.261
   Secondary or less                               295 (66.9%)         493 (63.9%)          788 (65.0%)       
   University/others                               50 (11.3%)          113 (14.7%)          163 (13.4%)       
  Work type                                                                                                   
   Private                                         35 (7.8%)           64 (8.3%)            99 (8.1%)         **0.001**
   Governmental                                    53 (11.8%)          155 (20.2%)          208 (17.1%)       
   Own business                                    13 (2.9%)           28 (3.7%)            41 (3.4%)         
   Unemployed                                      347 (77.5%)         520 (67.8%)          867 (71.4%)       
  Monthly family income (Saudi Riyal)                                                                         
   Low income (≤3,000)                             162 (37.2%)         194 (25.5%)          356 (29.7%)       \<**0.001**
   Lower limit of moderate income (3,001--6,000)   130 (29.9%)         256 (33.6%)          386 (32.2%)       
   Upper limit of moderate income (6,001--9,000)   94 (21.6%)          151 (19.8%)          245 (20.5%)       
   High income (\>9,000)                           49 (11.3%)          161 (21.1%)          210 (17.5%)       
  Residency                                                                                                   
   City                                            371 (80.8%)         630 (80.9%)          1,001 (80.9%)     \<**0.001**
   Village                                         88 (19.2%)          121 (15.5%)          209 (16.9%)       
   Desert                                          0 (0.0%)            28 (3.6%)            28 (2.3%)         
  Body mass index                                                                                             
   Mean ± SD                                       27.7±7.6            29.2±7.5             28.6±7.6          **0.001**
   Underweight                                     36 (8.3%)           34 (4.4%)            70 (5.8%)         **0.001**
   Normal                                          131 (30.3%)         195 (25.2%)          326 (27.0%)       
   Overweight                                      131 (30.3%)         225 (29.1%)          356 (29.5%)       
   Obese                                           135 (31.2%)         319 (41.3%)          454 (37.6%)       
  Smoking status                                                                                              
   Current                                         181 (40.0%)         234 (30.0%)          415 (33.7%)       \<**0.001**
   Past                                            70 (15.5%)          78 (10.0%)           148 (12.0%)       
   Never                                           202 (44.6%)         467 (59.9%)          669 (54.3%)       

**Notes:** Bold indicates statistically significant results (*P*\<0.05). A BMI below 18.5 kg/[@b2-ndt-12-897] is considered underweight. A BMI of 18.5 to 24.9 kg/m^2^ is considered healthy (normal). A BMI of 25 to 29.9 kg/m^2^ is considered overweight. A BMI of 30 kg/m^2^ or higher is considered obese

**Abbreviation:** SD, standard deviation.

###### 

Current and previous uses of antipsychotic medications by type of patient setting (N=1,246)

  Classes of antipsychotics used   Current      *P*-value    Previous     *P*-value                                            
  -------------------------------- ------------ ------------ ------------ ------------- ------------ ------------ ------------ -------------
  Any antipsychotic                410 (94.3)   462 (65.7)   872 (76.6)   \<**0.001**   318 (89.8)   416 (68.1)   734 (76.1)   \<**0.001**
  Low potency first-generation     26 (6.0)     40 (5.7)     66 (5.8)     0.84          19 (5.4)     44 (7.2)     63 (6.5)     0.266
   Chlorpromazine                  25 (5.7)     32 (4.6)     57 (5.0)     0.369         17 (4.8)     31 (5.1)     48 (5.0)     0.852
   Thioridazine                    0 (0.0)      0 (0.0)      0 (0.0)      --            2 (0.6)      1 (0.2)      3 (0.3)      0.558
   Sulpiride                       1 (0.2)      8 (1.1)      9 (0.8)      0.165         2 (0.6)      13 (2.1)     15 (1.6)     0.059
  High potency first-generation    113 (26.0)   78 (11.1)    191 (16.8)   \<**0.001**   100 (28.2)   113 (18.5)   213 (22.1)   \<**0.001**
   Haloperidol                     87 (20.0)    44 (6.3)     131 (11.5)   \<**0.001**   80 (22.6)    60 (9.8)     140 (14.5)   \<**0.001**
   Trifluoperazine                 8 (1.8)      20 (2.8)     28 (2.5)     0.287         13 (3.7)     48 (7.9)     61 (6.3)     **0.010**
   Fluphenazine                    15 (3.4)     4 (0.6)      19 (1.7)     \<**0.001**   7 (2.0)      8 (1.3)      15 (1.6)     0.419
   Flupentixol                     6 (1.4)      7 (1.0)      13 (1.1)     0.575         9 (2.5)      6 (1.0)      15 (1.6)     0.059
   Zuclopenthixol                  0 (0.0)      6 (0.9)      6 (0.5)      0.088         3 (0.8)      0 (0.0)      3 (0.3)      **0.049**
  Second-generation                365 (83.9)   405 (57.6)   770 (67.7)   \<**0.001**   277 (78.2)   331 (54.2)   608 (63.0)   \<**0.001**
   Risperidone                     159 (36.6)   165 (23.5)   324 (28.5)   \<**0.001**   140 (39.5)   159 (26.0)   299 (31.0)   \<**0.001**
   Olanzapine                      137 (31.5)   133 (18.9)   270 (23.7)   \<**0.001**   117 (33.1)   110 (18.0)   227 (23.5)   \<**0.001**
   Quetiapine                      68 (15.6)    104 (14.8)   172 (15.1)   0.701         58 (16.4)    71 (11.6)    129 (13.4)   **0.036**
   Aripiprazole                    52 (12.0)    55 (7.8)     107 (9.4)    **0.020**     16 (4.5)     27 (4.4)     43 (4.5)     0.942
   Paliperidone                    29 (6.7)     20 (2.8)     49 (4.3)     **0.002**     10 (2.8)     10 (1.6)     20 (2.1)     0.212
   Clozapine                       23 (5.3)     12 (1.7)     35 (3.1)     **0.001**     12 (3.4)     11 (1.8)     23 (2.4)     0.119
   Amisulpride                     9 (2.1)      5 (0.7)      14 (1.2)     **0.043**     3 (0.8)      5 (0.8)      8 (0.8)      1.000

**Note:** Bold indicates statistically significant results (*P*\<0.05).

###### 

Current and previous uses of antidepressant medications by type of patient setting (N=1,246)

  Classes of antidepressants used   Current     *P*-value    Previous     *P*-value                                           
  --------------------------------- ----------- ------------ ------------ ------------- ----------- ------------ ------------ -------------
  Any antidepressant                91 (20.9)   380 (54.1)   471 (41.4)   \<**0.001**   74 (20.9)   298 (48.8)   372 (38.5)   \<**0.001**
  SSRI antidepressants              61 (14.0)   265 (37.7)   326 (28.6)   \<**0.001**   44 (12.4)   196 (32.1)   240 (24.9)   \<**0.001**
   Escitalopram                     22 (5.1)    107 (15.2)   129 (11.3)   \<**0.001**   13 (3.7)    63 (10.3)    76 (7.9)     \<**0.001**
   Fluoxetine                       15 (3.4)    67 (9.5)     82 (7.2)     \<**0.001**   16 (4.5)    56 (9.2)     72 (7.5)     **0.008**
   Citalopram                       3 (0.7)     39 (5.5)     42 (3.7)     \<**0.001**   3 (0.8)     44 (7.2)     47 (4.9)     \<**0.001**
   Paroxetine                       8 (1.8)     28 (4.0)     36 (3.2)     **0.045**     7 (2.0)     19 (3.1)     26 (2.7)     0.295
   Fluvoxamine                      8 (1.8)     16 (2.3)     24 (2.1)     0.618         7 (2.0)     18 (2.9)     25 (2.6)     0.361
   Sertraline                       5 (1.1)     14 (2.0)     19 (1.7)     0.281         2 (0.6)     13 (2.1)     15 (1.6)     0.059
  Tricyclic antidepressants         8 (1.8)     62 (8.8)     70 (6.2)     \<**0.001**   15 (4.2)    88 (14.4)    103 (10.7)   \<**0.001**
   Amitriptyline                    7 (1.6)     51 (7.3)     58 (5.1)     \<**0.001**   13 (3.7)    74 (12.1)    87 (9.0)     \<**0.001**
   Imipramine                       0 (0.0)     6 (0.9)      6 (0.5)      0.088         0 (0.0)     8 (1.3)      8 (0.8)      0.057
   Clomipramine                     1 (0.2)     4 (0.6)      5 (0.4)      0.655         1 (0.3)     7 (1.1)      8 (0.8)      0.270
   Maprotiline                      0 (0.0)     1 (0.1)      1 (0.1)      1.000         1 (0.3)     1 (0.2)      2 (0.2)      1.000
  Other antidepressants             34 (7.8)    132 (18.8)   166 (14.6)   \<**0.001**   23 (6.5)    88 (14.4)    111 (11.5)   \<**0.001**
   Mirtazapine                      16 (3.7)    81 (11.5)    97 (8.5)     \<**0.001**   13 (3.7)    50 (8.2)     63 (6.5)     **0.006**
   Venlafaxine                      16 (3.7)    42 (6.0)     58 (5.1)     0.087         8 (2.3)     35 (5.7)     43 (4.5)     **0.012**
   Agomelatine                      1 (0.2)     7 (1.0)      8 (0.7)      0.164         2 (0.6)     0 (0.0)      2 (0.2)      0.134
   Duloxetine                       1 (0.2)     5 (0.7)      6 (0.5)      0.416         0 (0.0)     6 (1.0)      6 (0.6)      0.091
   Desvenlafaxine                   0 (0.0)     2 (0.3)      2 (0.2)      0.527         0 (0.0)     1 (0.2)      1 (0.1)      1.000
   Trazodone                        0 (0.0)     1 (0.1)      1 (0.1)      1.000         1 (0.3)     1 (0.2)      2 (0.2)      1.000
   Maprotiline                      0 (0.0)     1 (0.1)      1 (0.1)      1.000         1 (0.3)     1 (0.2)      2 (0.2)      1.000

**Note:** Bold indicates statistically significant results (*P*\<0.05).

**Abbreviation:** SSRI, Selective serotonin reuptake inhibitor.

###### 

Current and previous uses of other psychotropic medications by type of patient setting (N=1,246)

  Other psychotropics used   Current      *P*-value    Previous     *P*-value                                           
  -------------------------- ------------ ------------ ------------ ------------- ------------ ----------- ------------ -------------
  Mood stabilizers           177 (40.7)   141 (20.1)   318 (27.9)   \<**0.001**   129 (36.4)   98 (16.0)   227 (23.5)   \<**0.001**
   Valproate                 123 (28.3)   88 (12.5)    211 (18.5)   \<**0.001**   85 (24.0)    47 (7.7)    132 (13.7)   \<**0.001**
   Carbamazepine             36 (8.3)     31 (4.4)     67 (5.9)     **0.007**     30 (8.5)     33 (5.4)    63 (6.5)     0.062
   Lithium                   16 (3.7)     13 (1.8)     29 (2.5)     0.057         11 (3.1)     15 (2.5)    26 (2.7)     0.546
   Lamotrigine               10 (2.3)     16 (2.3)     26 (2.3)     0.980         12 (3.4)     8 (1.3)     20 (2.1)     **0.029**
  Antianxiety                58 (13.3)    13 (1.8)     71 (6.2)     \<**0.001**   29 (8.2)     6 (1.0)     35 (3.6)     \<**0.001**
   Clonazepam                32 (7.4)     8 (1.1)      40 (3.5)     \<**0.001**   12 (3.4)     2 (0.3)     14 (1.5)     \<**0.001**
   Lorazepam                 23 (5.3)     1 (0.1)      24 (2.1)     \<**0.001**   18 (5.1)     2 (0.3)     20 (2.1)     \<**0.001**
   Alprazolam                2 (0.5)      3 (0.4)      5 (0.4)      1.000         0 (0.0)      2 (0.3)     2 (0.2)      0.535
   Diazepam                  1 (0.2)      1 (0.1)      2 (0.2)      1.000         0 (0.0)      0 (0.0)     0 (0.0)      --
  Others                     0 (0.0)      2 (0.3)      2 (0.2)      0.527         1 (0.3)      0 (0.0)     1 (0.1)      0.367
   Atomoxetine               0 (0.0)      1 (0.1)      1 (0.1)      1.000         0 (0.0)      0 (0.0)     0 (0.0)      --
   Methylphenidate           0 (0.0)      1 (0.1)      1 (0.1)      1.000         1 (0.3)      0 (0.0)     1 (0.1)      0.367

**Notes:** Bold indicates statistically significant results (*P*\<0.05). Dash indicates data not applicable.

###### 

Prevalence rates of current uses of psychotropic medications by psychiatric diagnoses and type of patient setting (N= 1,246)

  Classes of psychotropics used      Primary psychotic disorders (%)                         Primary bipolar disorders (%)                          Primary depressive disorders (%)                       Primary anxiety disorders (%)                           Personality disorders (%)                             Secondary psychiatric disorders (%)   Multiple disorders (%)                                 Other disorders (%)
  ---------------------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------- ----------------------------------------------------- ------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  Inpatient                                                                                                                                                                                                                                                                                                                                                                                                           
   Any antipsychotic                 247 (98.0)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   89 (96.7)                                              21 (77.8)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   4 (66.7)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}     6 (85.7)                                              7 (100.0)                             15 (88.2)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   7 (87.5)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}
    First-generation, low potency    16 (6.3)                                                4 (4.3)                                                1 (3.7)                                                0 (0.0)                                                 0 (0.0)                                               0 (0.0)                               0 (0.0)                                                2 (25.0)
    First-generation, high potency   78 (3 1.0)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   19 (20.7)                                              3 (11.1)                                               0 (0.0)                                                 1 (14.3)                                              0 (0.0)                               3 (17.6)                                               3 (37.5)
    Second-generation                219 (86.9)                                              79 (85.9)                                              20 (74.1)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   4 (66.7)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}     6 (85.7)                                              7 (100.0)                             12 (70.6)                                              5 (62.5)
   Any antidepressant                38 (15.1)                                               2 (2.2)                                                21 (77.8)                                              4 (66.7)                                                3 (42.9)                                              3 (42.9)                              10 (58.8)                                              3 (37.5)
    SSRI antidepressants             27 (10.7)                                               1 (1.1)                                                15 (55.6)                                              4 (66.7)                                                2 (28.6)                                              3 (42.9)                              3 (17.6)                                               2 (25.0)
    Tricyclic antidepressants        5 (2.0)                                                 0 (0.0)                                                1 (3.7)                                                0 (0.0)                                                 1 (14.3)                                              0 (0.0)                               0 (0.0)                                                1 (12.5)
    Other antidepressants            7 (2.8)                                                 1 (1.1)                                                11 (40.7)                                              2 (33.3)                                                0 (0.0)                                               1 (14.3)                              7 (41.2)                                               0 (0.0)
   Mood stabilizers                  76 (30.2)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}    71 (77.2)                                              8 (29.6)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}    0 (0.0)                                                 2 (28.6)                                              3 (42.9)                              8 (47.1)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}    3 (37.5)
   Antianxiety                       27 (10.7)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}    25 (27.2)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   3 (11.1)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}    1 (16.7)                                                1 (14.3)                                              0 (0.0)                               0 (0.0)                                                1 (12.5)
  Outpatient                                                                                                                                                                                                                                                                                                                                                                                                          
   Any antipsychotic                 199 (94.3)                                              76 (93.8)                                              73 (49.7)                                              19 (18.1)                                               3 (30.0)                                              29 (85.3)                             31 (53.4)                                              14 (45.2)
    First-generation, low potency    14 (6.6)                                                3 (3.7)                                                15 (10.2)                                              1 (1.0)                                                 0 (0.0)                                               1 (2.9)                               2 (3.4)                                                3 (9.7)
    First-generation, high potency   38 (18.0)                                               15 (18.5)                                              6 (4.1)                                                6 (5.7)                                                 0 (0.0)                                               2 (5.9)                               4 (6.9)                                                4 (12.9)
    Second-generation                181 (85.8)                                              68 (84.0)                                              58 (39.5)                                              12 (11.4)                                               3 (30.0)                                              28 (82.4)                             27 (46.6)                                              10 (32.3)
   Any antidepressant                46 (21.8)                                               17 (21.0)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   134 (91.2)                                             100 (95.2)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   8 (80.0)                                              8 (23.5)                              38 (65.5)                                              17 (54.8)
    SSRI antidepressants             34 (16.1)                                               12 (14.8)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   84 (57.1)                                              80 (76.2)                                               5 (50.0)                                              5 (14.7)                              25 (43.1)                                              10 (32.3)
    Tricyclic antidepressants        5 (2.4)                                                 2 (2.5)                                                26 (17.7)                                              16 (15.2)                                               0 (0.0)                                               1 (2.9)                               8 (13.8)                                               4 (12.9)
    Other antidepressants            11 (5.2)                                                4 (4.9)                                                55 (37.4)                                              30 (28.6)                                               5 (50.0)[\*](#tfn7-ndt-12-897){ref-type="table-fn"}   4 (11.8)                              17 (29.3)                                              4 (12.9)
   Mood stabilizers                  42 (19.9)                                               60 (74.1)                                              8 (5.4)                                                0 (0.0)                                                 3 (30.0)                                              7 (20.6)                              9 (15.5)                                               4 (12.9)
   Antianxiety                       4 (1.9)                                                 4 (4.9)                                                1 (0.7)                                                0 (0.0)                                                 0 (0.0)                                               0 (0.0)                               1 (1.7)                                                0 (0.0)

**Note:**

Indicates significantly (P\<0.05) higher use among inpatients or outpatients.

**Abbreviation:** SSRI, Selective serotonin reuptake inhibitor.
